Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Research & Development (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Research & Development for 7 consecutive years, with $86.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development changed N/A to $86.1 million in Q3 2025 year-over-year; TTM through Aug 2025 was $230.9 million, a N/A change, with the full-year FY2024 number at $221.6 million, up 17.17% from a year prior.
  • Research & Development was $86.1 million for Q3 2025 at Nurix Therapeutics, up from $48.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $86.1 million in Q3 2025 to a low of $23.0 million in Q1 2021.
  • A 5-year average of $44.3 million and a median of $46.0 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 87.53% in 2022, then rose 6.21% in 2023.
  • Nurix Therapeutics' Research & Development stood at $36.5 million in 2021, then increased by 26.21% to $46.1 million in 2022, then decreased by 0.63% to $45.8 million in 2023, then grew by 6.78% to $48.9 million in 2024, then soared by 76.04% to $86.1 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Research & Development are $86.1 million (Q3 2025), $48.9 million (Q2 2024), and $50.0 million (Q1 2024).